Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chujiao Hu

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Technology in Cancer Research & Treatment|April 9, 2024
Breast Cancer Prediction Based on Multiple Machine Learning AlgorithmsSheng Zhou, Chujiao Hu, Shanshan Wei, et al.
International Immunopharmacology|June 22, 2023
Reconsideration of interferon treatment for viral diseases: Lessons from SARS, MERS, and COVID-19Dan Ma, Ximin Wang, Min Li, et al.
Frontiers in Pharmacology|September 26, 2022
Discovery of novel <i>IDH1</i>-R132C inhibitors through structure-based virtual screeningChujiao Hu, Zhirui Zeng, Dan Ma, et al.
Frontiers in Immunology|October 3, 2022
A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapyRunsang Pan, Feng Pan, Zhirui Zeng, et al.
Communications Biology|February 16, 2026
CRISPR-Cas9 screening identifies ATOX1-driven cisplatin resistance mechanisms in liver cancer and evaluates targeted inhibitor efficacyChujiao Hu, Huading Tai, Renguang Zhu, et al.
Frontiers in Pharmacology|December 4, 2023
Integrated investigation and experimental validation of PPARG as an oncogenic driver: implications for prognostic assessment and therapeutic targeting in hepatocellular carcinomaYunsheng Ran, Chujiao Hu, Junzhao Wan, et al.
Bioorganic & Medicinal Chemistry Letters|December 15, 2019
Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitorChujiao Hu, Yu Zuo, Jingqiu Liu, et al.
Frontiers in Immunology|September 26, 2022
A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapyZhirui Zeng, Chujiao Hu, Wanyuan Ruan, et al.
Aging|March 18, 2024
Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapyWenpeng Cao, Jinzhi Lan, Chujiao Hu, et al.
Cell Communication and Signaling : CCS|August 28, 2025
Whole-gene CRISPR/cas9 library screen revealed targeting STAT6 increased the sensitivity of liver cancer to celecoxib via inhibiting arachidonic acid shuntingChujiao Hu, Zhirui Zeng, Xin Bao, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Technology in Cancer Research & Treatment|April 9, 2024
Breast Cancer Prediction Based on Multiple Machine Learning AlgorithmsSheng Zhou, Chujiao Hu, Shanshan Wei, et al.
International Immunopharmacology|June 22, 2023
Reconsideration of interferon treatment for viral diseases: Lessons from SARS, MERS, and COVID-19Dan Ma, Ximin Wang, Min Li, et al.
Frontiers in Pharmacology|September 26, 2022
Discovery of novel <i>IDH1</i>-R132C inhibitors through structure-based virtual screeningChujiao Hu, Zhirui Zeng, Dan Ma, et al.
Frontiers in Immunology|October 3, 2022
A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapyRunsang Pan, Feng Pan, Zhirui Zeng, et al.
Communications Biology|February 16, 2026
CRISPR-Cas9 screening identifies ATOX1-driven cisplatin resistance mechanisms in liver cancer and evaluates targeted inhibitor efficacyChujiao Hu, Huading Tai, Renguang Zhu, et al.
Frontiers in Pharmacology|December 4, 2023
Integrated investigation and experimental validation of PPARG as an oncogenic driver: implications for prognostic assessment and therapeutic targeting in hepatocellular carcinomaYunsheng Ran, Chujiao Hu, Junzhao Wan, et al.
Bioorganic & Medicinal Chemistry Letters|December 15, 2019
Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitorChujiao Hu, Yu Zuo, Jingqiu Liu, et al.
Frontiers in Immunology|September 26, 2022
A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapyZhirui Zeng, Chujiao Hu, Wanyuan Ruan, et al.
Aging|March 18, 2024
Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapyWenpeng Cao, Jinzhi Lan, Chujiao Hu, et al.
Cell Communication and Signaling : CCS|August 28, 2025
Whole-gene CRISPR/cas9 library screen revealed targeting STAT6 increased the sensitivity of liver cancer to celecoxib via inhibiting arachidonic acid shuntingChujiao Hu, Zhirui Zeng, Xin Bao, et al.
Pageof 2